Rebecca Yip

Rebecca Yip provides clients with data-driven analyses to understand the impact of policy and regulatory changes.

She applies her expertise in Medicare Part D, Congressional Budget Office-style scoring, and other modelling to assist clients in assessing the policy impact on various business lines.

Rebecca has more than 20 years’ experience in both the public and private sectors, providing analyses of health policy and market research involving federal programs, the commercial sector, and prescription drugs. Prior to joining Avalere, Rebecca was a principal analyst at the Congressional Budget Office where she led analyses for Medicare Part D and pharmacy policies. Rebecca has also held positions at Squire Patton Boggs, Pfizer Health Solutions, and PwC.

Rebecca has an MS in health policy and management from the University at Albany School of Public Health and a BA in biology from Barnard College.

Authored Content

New Avalere analysis finds Part D redesign via PDPRA would reduce average OOP costs by 23% for non-LIS beneficiaries, especially for certain drug classes and beneficiary groups by race and reason for entitlement.

The COVID-19 pandemic has brought renewed attention and urgency to mitigating access barriers to recommended vaccines.

As Congress renews focus on drug pricing reforms, an Avalere analysis examines recent trends in the Part D program’s subsidy payments and implications on stakeholder liabilities in the program.

For prescription drug fills across 4 therapeutic areas, Avalere analysis finds that Medicare Part D beneficiaries who receive the Low-Income Subsidy (LIS) have those drugs prescribed by a specialist less frequently than those who do not receive LIS.

With Congress likely to consider a second reconciliation bill in the near future that may include various drug-pricing and Medicare Part D reform policies as spending offsets, an updated Avalere analysis examines spending across classes with various availability of brand and generic drugs.

New Avalere analysis finds that 3 proposals to redesign the Part D benefit—H.R.19/S.3129, Prescription Drug Price Reduction Act (PDPRA), and Elijah Cummings Lower Drug Costs Now Act (H.R.3)—would increase 2023 mandatory manufacturer discounts by 80%, 81%, and 283%, respectively, with significant variation across therapeutic areas.

New Avalere analysis finds higher premiums for the enhanced standalone drug plans participating in the model.

Avalere analysis finds that 51% of all drug spending for non-LIS beneficiaries using insulins and enrolled in enhanced plans in 2018 was for products not participating in the model.

An Avalere analysis finds that, on average, non-LIS Medicare beneficiaries in Employer Group Waiver Plans (EGWPs) have higher utilization but lower out-of-pocket (OOP) costs than non-EGWP enrollees.

On May 13, Avalere experts discussed key issues and considerations for the healthcare industry as millions of Americans shift in and out of new sources of coverage due to COVID-19.

Avalere experts discussed the key issues and considerations for the healthcare industry as millions of Americans shift in and out of new sources of coverage.